Company Overview and News

 
KLCI pares gains as sellers outpace buyers

2018-10-16 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI pared some of its gains at midday break today, as sellers outpaced buyers at the local bourse, against the backdrop of modest gains at regional markets.
HLFBF 7113 BATS TPGVF 4162 5037 2089 9334 5199 3867 2836 HIPEF UPBMF 1082 5220 5681 7765 7066 0131 7123 TGLVY 5139 4588 0900 5819

 
KLCI declines amid trade dispute, US rate hike concerns

2018-10-15 theedgemarkets
KUALA LUMPUR (Oct 15): The FBM KLCI closed two points or 0.12% lower after Asian equities declined on US-China trade dispute and US interest rate hike concerns.
BATS 4162 BSMAF 9334 1818

 
KLCI pares gains as Trump threatens more tariffs on China

2018-10-15 theedgemarkets
KUALA LUMPUR (Oct 15): The FBM KLCI pared some of its gains at midday break, as regional markets remained jittery with U.S.President Donald Trump threatening to impose another round of tariffs on China.
HLFBF 5183 PECGF 1082 7113 5681 TPGVF 7006 5168 5014 9334 6033 5199 TGLVY 5238 4588 PNADF MYPRY HIPEF PNAGF HRGHY

 
KLCI stages technical rebound, reverses earlier loss

2018-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): The FBM KLCI staged a technical rebound today to snap its losing streak and rose 0.54% at mid-morning, reversing its earlier loss, lifted by index heavyweights Malayan Banking Bhd (Maybank) and Tenaga Nasional Bhd.
MLYBY MLYNF UPBMF 7036 BATS 4162 3034 2089 5014 9334 5199 2852 1155 5347 3301 3867 TNABY MYPRY 2836 TNABF HIPEF GEBHF

 
KLCI down 2% amid regional bloodbath

2018-10-11 theedgemarkets
KUALA LUMPUR (Oct 11): The FBM KLCI pared some of its losses at the midday break today, having gyrated between above and below the 1,700-point level during the morning session.
UPBMF 5681 BATS 4162 2089 9334 6033 5199 PNADF 5347 1201 3867 TNABY 6888 AXXTF TNABF HIPEF PNAGF

 
KLCI pares loss as region remains weaker

2018-10-09 theedgemarkets
KUALA LUMPUR (Oct 9): The FBM KLCI pared some of its losses at the midday break today, against a backdrop of weaker regional markets.
HLFBF UPBMF 7036 1082 5010 BATS 4162 2291 7765 3794 2089 5256 9334 5199 KLKBY 5139 2445 0900 8613 6888 AXXTF 5827 HIPEF 3719

 
KLCI remains in the red in tandem with regional markets

2018-10-09 theedgemarkets
KUALA LUMPUR (Oct 9): The FBM KLCI remained in negative zone at mid-morning today, in tandem with regional markets that were also mostly in the red.
SPMXF UPBMF 7036 1163 7087 ORHLF 5168 2089 5256 9334 4006 KLKBY 2445 SPMXY 5819 HRGHY

 
KLCI off to lacklustre start, tracks muted regional markets

2018-10-09 theedgemarkets
KUALA LUMPUR (Oct 9): The FBM KLCI got off to a lacklustre start this morning, tracking the muted regional markets.
5183 PECGF 7113 TPGVF 1163 5168 9334 CIMDF 7233 TGLVY KLKBY 1023 2445 HRGHY

 
KLCI pares loss, remains in red tracking regional markets

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): The FBM KLCI pared some of its loss at mid-morning today, but remained in the negative zone in line with its key regional peers.
HLFBF SPMXF UPBMF 7036 1082 7113 TPGVF BATS 4162 7087 2089 9334 7123 TGLVY SPMXY 5225 3026 3301 0026 1899 Q0F IHHHF GEBHF

 
KLCI falls 0.34%, tracks regional losses

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): The FBM KLCI fell early on Monday, tracking the losses at key regional markets, dragged by index-linked blue chips.
5183 PECGF 5703 5168 9334 HRGHY

 
KLCI stays negative, falls 0.43%

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): The FBM KLCI remained in the negative zone at the midday break today, and fell 0.43% in line with the decline at regional markets.
UPBMF 5088 7113 5010 TPGVF 5202 2089 9334 6033 5199 9113 TGLVY 0143 5139 4588 PNADF 3867 0900 6888 AXXTF 2836 HIPEF PNAGF

 
KLCI falls 0.38% in tandem with regional retreat

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): The FBM KLCI fell 0.38% at mid-morning today, tracking fragile regional markets.
UPBMF 7113 TPGVF BATS 4162 2291 5202 2089 9334 6033 9113 4634 TGLVY 5139 PNADF 5226 3301 NDAQ 0900 6888 5819 AXXTF 1902 PNAGF

 
KLCI remains in the red, tracks regional slump

2018-10-04 theedgemarkets
KUALA LUMPUR (Oct 4): The FBM KLCI retreated at the midday break, in line with slump at most regional markets.
HLFBF 5183 PECGF 1082 BATS 4162 7765 5014 9334 7123 5199 4588 3026 0026 5219 MYPRY HIPEF

 
KLCI stays shy of 1,800 as regional markets retreat

2018-10-02 theedgemarkets
KUALA LUMPUR (Oct 2): The FBM KLCI was hard pressed to find a firm footing in the morning session and remained below the crucial 1,800-point level at the midday break, as regional markets retreated.
HLFBF BRDBF UPBMF 1082 5168 2089 5256 5255 9334 5199 5210 4634 5139 4456 3026 0900 0026 7108 2836 HIPEF GEBHF HRGHY

 
FBM KLCI pares gains, subdued in line with region

2018-10-01 theedgemarkets
KUALA LUMPUR (Oct 1): The FBM KLCI pared some of its gains at mid-morning, keeping the local index subdued in line with the regional markets on the first trading day of the fourth quarter.
APEXF 7090 BATS 4162 2089 5256 9334 5199 5008 5843 1201 3026 3301 3867 2836 HIPEF PNAGF 7084 UPBMF 5681 5268 6033 PNADF 0026 1899

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...